CAR T cell News and Research

RSS

International conference features cutting-edge research studies on cancer immunotherapy

The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

1 Oct 2018

Loyola announces plans to produce CAR-T cells for treating cancer

Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma.

28 Sep 2018

Cell Medica successfully doses first patient with CMD-501 targeting pediatric neuroblastoma

Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma

20 Sep 2018

UK and European research collaborations receive vote of confidence by three major cancer charities

UK and European research collaborations in cancer research have received a vote of confidence by three major cancer charities, with an announcement today of approximately £30 million into six international projects.

20 Sep 2018

AACI/CCAF annual meeting to highlight perspectives on future of cancer research and care

Perspectives on the future of cancer research and care, including the latest on CAR T-cell therapy, Big Data management, and international partnerships, will highlight the 2018 joint annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum, September 30 – October 2, in Chicago.

6 Sep 2018

New personalized cellular therapy approved for use in the European Union

The European Commission has approved a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, making it the first chimeric antigen receptor (CAR) T cell therapy permitted for use in the European Union in two distinct indications.

27 Aug 2018

Study compares T-cell signaling patterns in two different CAR designs

CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined.

21 Aug 2018

Scientists find two molecules that may combat cancer and chronic infections

To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy approaches to kill cancer cells, including the CAR T cell therapy currently attracting broad public attention.

21 Aug 2018

New model of genetically engineered immune cells may help fight solid tumors

Scientists at Memorial Sloan Kettering Cancer Center announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

15 Aug 2018

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells.

14 Aug 2018

New CAR T-cell immunotherapy trial targets solid tumors

Seattle Children's has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors.

7 Aug 2018

Staggering prices slow insurers’ coverage of CAR-T cancer therapy

Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years.

17 Jul 2018

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.

30 Jun 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

25 Jun 2018

Cureworks collaborative aims to accelerate development of immunotherapies for pediatric cancer

Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer.

12 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Obsidian Therapeutics presents preclinical data on regulated IL12 and IL15 programs

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that the company presented preclinical data on its regulated IL12 and IL15 programs at the Annual Meeting of the American Society of Gene and Cell Therapy in Chicago, IL.

17 May 2018

Cancer Center at BIDMC announces launch of new Immunotherapy Institute

The Cancer Center at Beth Israel Deaconess Medical Center today announced the launch of a new clinical and research institute that will build on BIDMC's long history of leadership in immunotherapy and cell therapeutics.

3 May 2018